PMID- 15665573
OWN - NLM
STAT- MEDLINE
DCOM- 20050513
LR  - 20181201
IS  - 1598-9992 (Print)
IS  - 1598-9992 (Linking)
VI  - 44
IP  - 6
DP  - 2004 Dec
TI  - [Treatment of chronic hepatitis C].
PG  - 301-7
AB  - Chronic infection with HCV represents second most common cause of end-stage liver 
      diseases and hepatocellular carcinoma in Korea. The introduction of new agents 
      and regimens for the treatment of chronic hepatitis C, such as pegylated forms of 
      interferon-alpha (Peg-IFN) and combination with oral ribavirin has resulted in 
      substantial improvement in sustained virologic response (SVR) rates. SVR rate of 
      Peg-IFN and ribavirin combination therapy can be 40-46% of individuals infected 
      with genotype 1 and approximately 75-85% with genotype 2 and 3. Peg-IFN/ribavirin 
      combination therapy represents current standard therapy of chronic hepatitis C. 
      This article reviews the treatment objectives, outcomes, optimal regimens, 
      efficacy and predictors of response, monitoring during treatment, adverse events, 
      retreatment of persons who failed to respond to previous treatments, and 
      treatment of special patient groups in chronic hepatitis C.
FAU - Chang, Yun Jung
AU  - Chang YJ
AD  - Department of Internal Medicine, Korea University College of Medicine, Seoul 
      152-703, Korea.
FAU - Byun, Kwan Soo
AU  - Byun KS
LA  - kor
PT  - Journal Article
PT  - Review
PL  - Korea (South)
TA  - Korean J Gastroenterol
JT  - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
JID - 101189416
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (Recombinant Proteins)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 49717AWG6K (Ribavirin)
RN  - G8RGG88B68 (peginterferon alfa-2b)
RN  - Q46947FE7K (peginterferon alfa-2a)
SB  - IM
MH  - Drug Therapy, Combination
MH  - Hepatitis C, Chronic/*drug therapy
MH  - Humans
MH  - Interferon alpha-2
MH  - Interferon-alpha/administration & dosage
MH  - Polyethylene Glycols/administration & dosage
MH  - Recombinant Proteins
MH  - Ribavirin/administration & dosage
RF  - 33
EDAT- 2005/01/25 09:00
MHDA- 2005/05/14 09:00
CRDT- 2005/01/25 09:00
PHST- 2005/01/25 09:00 [pubmed]
PHST- 2005/05/14 09:00 [medline]
PHST- 2005/01/25 09:00 [entrez]
AID - 200412311 [pii]
PST - ppublish
SO  - Korean J Gastroenterol. 2004 Dec;44(6):301-7.